1. Clinical Outcomes of Pulmonary Embolism in Mexican Patients With COVID-19.
- Author
-
Bobadilla-Rosado, Luis O., Mier y Teran-Ellis, Santiago, Lopez-Pena, Gabriel, Anaya-Ayala, Javier E., and Hinojosa, Carlos A.
- Subjects
COVID-19 ,MEXICANS ,PULMONARY embolism ,TREATMENT effectiveness ,FIBRINOLYTIC agents ,INTENSIVE care units - Abstract
Coagulation abnormalities have been reported in COVID-19 patients, which may lead to an increased risk of Pulmonary Embolism (PE). We aimed to describe the clinical characteristics and outcomes of COVID-19 patients diagnosed with PE during their hospital stay. We analyzed patients with PE and COVID-19 in a tertiary center in Mexico City from April to October of 2020. A total of 26 (100%) patients were diagnosed with Pulmonary Embolism and COVID-19. We observed that 14 (54%) patients were receiving either prophylactic or full anticoagulation therapy, before PE diagnosis. We found a significant difference in mortality between the group with less than 7 days (83%) and the group with more than 7 days (15%) in Intensive Care Unit (P =.004); as well as a mean of 8 days for the mortality group compared with 20 days of hospitalization in the survivor group (P =.003). In conclusion, there is an urgent need to review antithrombotic therapy in these patients in order to improve clinical outcomes and decrease hospital overload. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF